Boehringer Ingelheim - Recruiting 18 years or older. - An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Patients With Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy.
Celgene Corporation - Recruiting 18 years or older. - An Open-label, Randomized, Phase 2, Parallel, Dose-ranging, Multicenter Study of Sotatercept for the Treatment of Patients With Anemia and Low- or Intermediate-1 Risk Myelodysplastic Syndromes or Non-proliferative Chronic Myelomonocytic Leukemia (CMML)..
Children's Oncology Group - Recruiting 4 years to 21 years. - A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation.
St. Jude Children's Research Hospital - Recruiting N/A to 21 years. - T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant.
Columbia University - Recruiting N/A to 22 years. - CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease.
Roswell Park Cancer Institute - Recruiting 18 years or older. - A Phase I Study of DEC205mAb-NY ESO 1 Fusion Protein (CDX-1401) Given With Adjuvant polyICLC in Conjunction With 5-Aza-2'Deoxycytidine (Decitabine) in Patients With MDS or Low Blast Count AML.
DEC-205/NY-ESO-1 fusion protein CDX-1401; poly ICLC; decitabine; laboratory biomarker analysis
Hospital Israelita Albert Einstein - Recruiting 18 years to 60 years. - Randomized Study to Compare Post Bone Marrow Transplant Cyclophosphamide With the Combination of Methotrexate Plus Calcineurin Inhibitor for Graft Versus Host Disease Prophylaxis.
ARM A Cyclophosphamide; ARM B Calcineurin inhibitor and methotrexate
Universittsklinikum Hamburg-Eppendorf - Recruiting 55 years to 70 years. - Comparison Between 5-azacytidine Treatment and 5-azacytidine Followed by Allogeneic Stem Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability.
allogeneic stem cell transplantation; 5-azacytidine until progress